Possible Role of Butyric Acid in Long‐Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation
Neurogastroenterology & Motility · 2025-12 · 37 (12)
DOI: 10.1111/nmo.70115 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 01.08.2025. Verfasst von Magdy El-Salhy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Fecal Microbiota Transplantation, Butyric Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helse Vest.
Abstract (Originalsprache)
Background
We previously found that the fecal levels of short‐chain fatty acids (SCFAs) changed in irritable bowel syndrome (IBS) patients at 1 month and 1 year after fecal microbiota transplantation (FMT). This study analyzed SCFAs at 2 and 3 years after FMT in the same IBS patients included in those previous studies.
Methods
This study randomized 113 IBS patients into placebo, 30‐g, and 60‐g groups, who received FMT with 30 g of their own feces and with 30 g and 60 g of the donor's feces, respectively. The patients completed four questionnaires to assess IBS symptoms, fatigue, and quality of life, and supplied fecal samples at the baseline and at 2 and 3 years after FMT. The fecal SCFA levels were measured using gas chromatography.
Results
The butyric acid level was significantly increased at 2 and 3 years after FMT in the 30‐g and 60‐g groups, and was significantly higher than that in the placebo group. The total SCFA and acetic acid levels decreased significantly in the 30‐g and 60‐g groups at 2 and 3 years after FMT, while the propionic acid level decreased in the 60‐g group at both time points. The butyric acid level was inversely correlated with IBS symptoms and fatigue. Conclusion and Inferences The increased butyric acid levels in IBS patients at 2 and 3 years after FMT and their inverse correlation with both IBS symptoms and fatigue suggest that butyric acid contributes to the long‐term improvement seen after FMT ( www.clinicaltrials.gov : NCT03822299).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Department of Medicine, National Centre for Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway.
- Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID-Profile: Jørgen Valeur
Förderung
- Helse Vest
Zitieren
APA
El-Salhy, M., Valeur, J., Brønstad, I., Gilja, O. H., & Hatlebakk, J. G. (2025). Possible Role of Butyric Acid in Long‐Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation. Neurogastroenterology & Motility, 37(12). https://doi.org/10.1111/nmo.70115
Vancouver
El-Salhy M, Valeur J, Brønstad I, Gilja OH, Hatlebakk JG. Possible Role of Butyric Acid in Long‐Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation. Neurogastroenterology & Motility. 2025;37(12). doi:10.1111/nmo.70115
BibTeX
@article{ElSalhy2025,
author = {El-Salhy, Magdy and Valeur, Jørgen and Brønstad, Ingeborg and Gilja, Odd Helge and Hatlebakk, Jan Gunnar},
title = {Possible Role of Butyric Acid in Long‐Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation},
journal = {Neurogastroenterology & Motility},
year = {2025},
volume = {37},
number = {12},
doi = {10.1111/nmo.70115}
}
EUVIMED